B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single‐arm cohort study of telitacicept

B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single‐arm cohort study of telitacicept

Abstract Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with B‐cell hyperactivity. Telitacicept is a transmembrane activator, calcium modulator, and cyclophilin ligand interactor‐Fc fusion protein, which can neutralize both B‐cell lymphocyte stimulator and a prol...

Full description

Bibliographic Details
Main Authors: Lanlan Ji, Yan Geng, Xiaohui Zhang, Xuerong Deng, Zhibo Song, Meng Tan, Ying Tan, Chenxue Qu, Zhuoli Zhang
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:MedComm
Subjects:
B cell inhibitor
transmembrane activator, calcium modulator and cyclophilin ligand interactor (TACI)
lupus
telitacicept
B lymphocyte stimulator (BLyS)
a proliferation‐inducing ligand (APRIL)
Online Access:https://doi.org/10.1002/mco2.515

Internet

https://doi.org/10.1002/mco2.515

Similar Items